A live-cell image-based machine learning strategy for reducing variability in PSC differentiation systems

Artificial intelligence for high content imaging in drug discovery

Artificial intelligence (AI) and high-content imaging (HCI) are contributing to advancements in drug discovery, propelled by the recent progress in deep neural networks. This review highlights AI's role in analysis of HCI data from fixed and live-cell imaging, enabling novel label-free and multi-channel fluorescent screening methods, and improving compound profiling. HCI experiments are rapid and cost-effective, facilitating large data set accumulation for AI model training. However, the success of AI in drug discovery also depends on high-quality data, reproducible experiments, and robust validation to ensure model performance. Despite challenges like the need for annotated compounds and managing vast image data, AI's potential in phenotypic screening and drug profiling is significant. Future improvements in AI, including increased interpretability and integration of multiple modalities, are expected to solidify AI and HCI's role in drug discovery.

Applications of machine learning in time-domain fluorescence lifetime imaging: a review

Many medical imaging modalities have benefited from recent advances in Machine Learning (ML), specifically in deep learning, such as neural networks. Computers can be trained to investigate and enhance medical imaging methods without using valuable human resources. In recent years, Fluorescence Lifetime Imaging (FLIm) has received increasing attention from the ML community. FLIm goes beyond conventional spectral imaging, providing additional lifetime information, and could lead to optical histopathology supporting real-time diagnostics. However, most current studies do not use the full potential of machine/deep learning models. As a developing image modality, FLIm data are not easily obtainable, which, coupled with an absence of standardisation, is pushing back the research to develop models which could advance automated diagnosis and help promote FLIm. In this paper, we describe recent developments that improve FLIm image quality, specifically time-domain systems, and we summarise sensing, signal-to-noise analysis and the advances in registration and low-level tracking. We review the two main applications of ML for FLIm: lifetime estimation and image analysis through classification and segmentation. We suggest a course of action to improve the quality of ML studies applied to FLIm. Our final goal is to promote FLIm and attract more ML practitioners to explore the potential of lifetime imaging.

Matrigel Tunes H9 Stem Cell-Derived Human Cerebral Organoid Development

Human cerebral organoids are readily generated from human embryonic stem cells and human induced pluripotent stem cells and are useful in studying human neurodevelopment. Recent work with human cerebral organoids have explored the creation of different brain regions and the impacts of soluble and mechanical cues. Matrigel is a gelatinous, heterogenous mixture of extracellular matrix proteins, morphogens, and growth factors secreted by Engelbreth-Holm-Swarm mouse sarcoma cells. It is a core component of almost all cerebral organoid protocols, generally supporting neuroepithelial budding and tissue polarization; yet, its roles and effects beyond its general requirement in organoid protocols are not well understood, and its mode of delivery is variable, including the embedding of organoids within it or its delivery in soluble form. Given its widespread usage, we asked how H9 stem cell-derived hCO development and composition are affected by Matrigel dosage and delivery method. We found Matrigel exposure influences organoid size, morphology, and cell type composition. We also showed that greater amounts of Matrigel promote an increase in the number of choroid plexus (ChP) cells, and this increase is regulated by the BMP4 pathway. These results illuminate the effects of Matrigel on human cerebral organoid development and the importance of delivery mode and amount on organoid phenotype and composition.

Non-Contrasted CT Radiomics for SAH Prognosis Prediction

Subarachnoid hemorrhage (SAH) denotes a serious type of hemorrhagic stroke that often leads to a poor prognosis and poses a significant socioeconomic burden. Timely assessment of the prognosis of SAH patients is of paramount clinical importance for medical decision making. Currently, clinical prognosis evaluation heavily relies on patients' clinical information, which suffers from limited accuracy. Non-contrast computed tomography (NCCT) is the primary diagnostic tool for SAH. Radiomics, an emerging technology, involves extracting quantitative radiomics features from medical images to serve as diagnostic markers. However, there is a scarcity of studies exploring the prognostic prediction of SAH using NCCT radiomics features. The objective of this study is to utilize machine learning (ML) algorithms that leverage NCCT radiomics features for the prognostic prediction of SAH. Retrospectively, we collected NCCT and clinical data of SAH patients treated at Beijing Hospital between May 2012 and November 2022. The modified Rankin Scale (mRS) was utilized to assess the prognosis of patients with SAH at the 3-month mark after the SAH event. Based on follow-up data, patients were classified into two groups: good outcome (mRS ≤ 2) and poor outcome (mRS > 2) groups. The region of interest in NCCT images was delineated using 3D Slicer software, and radiomic features were extracted. The most stable and significant radiomic features were identified using the intraclass correlation coefficient, t-test, and least absolute shrinkage and selection operator (LASSO) regression. The data were randomly divided into training and testing cohorts in a 7:3 ratio. Various ML algorithms were utilized to construct predictive models, encompassing logistic regression (LR), support vector machine (SVM), random forest (RF), light gradient boosting machine (LGBM), adaptive boosting (AdaBoost), extreme gradient boosting (XGBoost), and multi-layer perceptron (MLP). Seven prediction models based on radiomic features related to the outcome of SAH patients were constructed using the training cohort. Internal validation was performed using five-fold cross-validation in the entire training cohort. The receiver operating characteristic curve, accuracy, precision, recall, and f-1 score evaluation metrics were employed to assess the performance of the classifier in the overall dataset. Furthermore, decision curve analysis was conducted to evaluate model effectiveness. The study included 105 SAH patients. A comprehensive set of 1316 radiomics characteristics were initially derived, from which 13 distinct features were chosen for the construction of the ML model. Significant differences in age were observed between patients with good and poor outcomes. Among the seven constructed models, model_SVM exhibited optimal outcomes during a five-fold cross-validation assessment, with an average area under the curve (AUC) of 0.98 (standard deviation: 0.01) and 0.88 (standard deviation: 0.08) on the training and testing cohorts, respectively. In the overall dataset, model_SVM achieved an accuracy, precision, recall, f-1 score, and AUC of 0.88, 0.84, 0.87, 0.84, and 0.82, respectively, in the testing cohort. Radiomics features associated with the outcome of SAH patients were successfully obtained, and seven ML models were constructed. Model_SVM exhibited the best predictive performance. The radiomics model has the potential to provide guidance for SAH prognosis prediction and treatment guidance.